Investing.com - Financial Markets Worldwide

Egetis Therapeutics AB (publ) (EGTX)

Stockholm
Currency in SEK
5.38
0.00(0.00%)
Closed·

EGTX Financial Summary

Key Ratios

P/E Ratio-3.58
Price/Book3.04
Debt / Equity24.58%
Return on Equity-73.19%
Dividend Yield0.00%
EBITDA-319.10M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa40.6638.222.657.646.1
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa-144.51-58.4-12046.634.5
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-177.06-105.2-197-311.3-321.8
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-178.02-104.5-193.8-326.9-343.6
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa717569.3561.1760.2792.3
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa70.1439.249.4103.9204.2
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa630.72527506.2545.6492.9
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa-62.98-90.55-112.39-159.79-105.33
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-134.64-130.1-173.5-278.4-227.9
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-59.54-6-1.7--1.2
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa228.41-8.9155.7458.9270.9
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa32.75-143.9-16.3175.747.6
* In Millions of SEK (except for per share items)

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 12.00
(+123.05% Upside)

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
-0.17 / -0.19
Revenue / Forecast
12.70M / 24.70M
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Egetis Therapeutics AB's earnings for the latest quarter?

The Egetis Therapeutics AB EPS (TTM) is -1.03. Egetis Therapeutics AB reported sales of 12.70, net income of -62.90, and EPS of -0.17 for the latest quarter.

What was Egetis Therapeutics AB's net income for the latest quarter?

Egetis Therapeutics AB's net income for the latest quarter was -62.90.

How did Egetis Therapeutics AB's performance compare year-over-year in the latest quarter?

The company's revenue moved from 10.80 in the previous quarter to 12.70 in the latest quarter, and net income moved from -110.50 to -62.90 compared to the previous quarter.

What is Egetis Therapeutics AB's net profit margin on a TTM basis?

Egetis Therapeutics AB's trailing twelve months (TTM) net profit margin is -745.34%.

How does Egetis Therapeutics AB's debt to equity ratio compare to industry standards?

Egetis Therapeutics AB's total debt-to-equity ratio is 24.58%.

What is Egetis Therapeutics AB's return on investment on a TTM basis?

Egetis Therapeutics AB's trailing twelve months (TTM) return on investment (ROI) is -73.19%.

Did Egetis Therapeutics AB gain or lose cash last quarter?

In the latest quarter, Egetis Therapeutics AB's net change in cash was -78.20 million.

What were Egetis Therapeutics AB's total assets and liabilities in the latest quarter?

As of the latest quarter, Egetis Therapeutics AB reported total assets of 724.10 million and total liabilities of 199.70 million.

How has Egetis Therapeutics AB's total revenue grown this year?

Egetis Therapeutics AB's total revenue was 10.80 in the previous quarter and 12.70 in the latest quarter.

What is Egetis Therapeutics AB's gross margin on a TTM basis?

Egetis Therapeutics AB's trailing twelve months (TTM) gross margin is 60.17%.

What was Egetis Therapeutics AB's revenue per share for the latest quarter?

Egetis Therapeutics AB's revenue per share for the latest quarter was 0.76.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.